Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study

Carlo Salvarani, Fabrizio Cantini, Laura Niccoli, Maria Grazia Catanoso, Pierluigi Macchioni, Lia Pulsatelli, Angela Padula, Ignazio Olivieri, Luigi Boiardi

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Objective. To investigate whether infliximab has a steroid-sparing effect in the treatment of patients with polymyalgia rheumatica (PMR) who are resistant to corticosteroid (CS) therapy and have had CS-related side effects. Methods. In a pilot study, infliximab 3 mg/kg was administered at weeks 0, 2, and 6 in 4 patients with relapsing PMR who were not able to reduce their prednisone dose below 7.5-12.5 mg/day and who had experienced multiple vertebral fractures. The patients were regularly monitored for clinical signs/symptoms and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 (IL-6) during the one-year followup period. Results. Two patients had a complete response to infliximab with clinical remission 2 weeks after the first infusion. At this time ESR and IL-6 values were normal and the patients were able to suspend prednisone. Normal ESR, CRP, and IL-6 levels persisted after the suspension of infliximab and prednisone during the followup period, paralleling the clinical remission. The third patient had a complete and persistent clinical remission 2 weeks after the first infusion, although IL-6 levels remained elevated during the followup period despite the normalization of ESR values. These 3 patients were symptom-free with normal ESR and CRP at the end of 1-year of followup. The fourth patient had continuous clinical activity associated with persistently elevated acute phase reactants, although IL-6 levels measured during followup were lower compared to baseline values and the patient was able to reduce prednisone dosage to 5 mg/day. Conclusion. Our encouraging results suggest that a controlled study may assess the efficacy of infliximab as CS-sparing drug in PMR.

Original languageEnglish
Pages (from-to)760-763
Number of pages4
JournalJournal of Rheumatology
Volume30
Issue number4
Publication statusPublished - Apr 1 2003

Fingerprint

Polymyalgia Rheumatica
Blood Sedimentation
Interleukin-6
Prednisone
C-Reactive Protein
Adrenal Cortex Hormones
Therapeutics
Infliximab
Acute-Phase Proteins
Signs and Symptoms
Suspensions
Reference Values
Steroids

Keywords

  • Infliximab
  • Polymyalgia rheumatica
  • Relapsing disease

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Salvarani, C., Cantini, F., Niccoli, L., Catanoso, M. G., Macchioni, P., Pulsatelli, L., ... Boiardi, L. (2003). Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study. Journal of Rheumatology, 30(4), 760-763.

Treatment of refractory polymyalgia rheumatica with infliximab : A pilot study. / Salvarani, Carlo; Cantini, Fabrizio; Niccoli, Laura; Catanoso, Maria Grazia; Macchioni, Pierluigi; Pulsatelli, Lia; Padula, Angela; Olivieri, Ignazio; Boiardi, Luigi.

In: Journal of Rheumatology, Vol. 30, No. 4, 01.04.2003, p. 760-763.

Research output: Contribution to journalArticle

Salvarani, C, Cantini, F, Niccoli, L, Catanoso, MG, Macchioni, P, Pulsatelli, L, Padula, A, Olivieri, I & Boiardi, L 2003, 'Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study', Journal of Rheumatology, vol. 30, no. 4, pp. 760-763.
Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L et al. Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study. Journal of Rheumatology. 2003 Apr 1;30(4):760-763.
Salvarani, Carlo ; Cantini, Fabrizio ; Niccoli, Laura ; Catanoso, Maria Grazia ; Macchioni, Pierluigi ; Pulsatelli, Lia ; Padula, Angela ; Olivieri, Ignazio ; Boiardi, Luigi. / Treatment of refractory polymyalgia rheumatica with infliximab : A pilot study. In: Journal of Rheumatology. 2003 ; Vol. 30, No. 4. pp. 760-763.
@article{269626f796fe4871a54f0c02a24d60ce,
title = "Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study",
abstract = "Objective. To investigate whether infliximab has a steroid-sparing effect in the treatment of patients with polymyalgia rheumatica (PMR) who are resistant to corticosteroid (CS) therapy and have had CS-related side effects. Methods. In a pilot study, infliximab 3 mg/kg was administered at weeks 0, 2, and 6 in 4 patients with relapsing PMR who were not able to reduce their prednisone dose below 7.5-12.5 mg/day and who had experienced multiple vertebral fractures. The patients were regularly monitored for clinical signs/symptoms and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 (IL-6) during the one-year followup period. Results. Two patients had a complete response to infliximab with clinical remission 2 weeks after the first infusion. At this time ESR and IL-6 values were normal and the patients were able to suspend prednisone. Normal ESR, CRP, and IL-6 levels persisted after the suspension of infliximab and prednisone during the followup period, paralleling the clinical remission. The third patient had a complete and persistent clinical remission 2 weeks after the first infusion, although IL-6 levels remained elevated during the followup period despite the normalization of ESR values. These 3 patients were symptom-free with normal ESR and CRP at the end of 1-year of followup. The fourth patient had continuous clinical activity associated with persistently elevated acute phase reactants, although IL-6 levels measured during followup were lower compared to baseline values and the patient was able to reduce prednisone dosage to 5 mg/day. Conclusion. Our encouraging results suggest that a controlled study may assess the efficacy of infliximab as CS-sparing drug in PMR.",
keywords = "Infliximab, Polymyalgia rheumatica, Relapsing disease",
author = "Carlo Salvarani and Fabrizio Cantini and Laura Niccoli and Catanoso, {Maria Grazia} and Pierluigi Macchioni and Lia Pulsatelli and Angela Padula and Ignazio Olivieri and Luigi Boiardi",
year = "2003",
month = "4",
day = "1",
language = "English",
volume = "30",
pages = "760--763",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Treatment of refractory polymyalgia rheumatica with infliximab

T2 - A pilot study

AU - Salvarani, Carlo

AU - Cantini, Fabrizio

AU - Niccoli, Laura

AU - Catanoso, Maria Grazia

AU - Macchioni, Pierluigi

AU - Pulsatelli, Lia

AU - Padula, Angela

AU - Olivieri, Ignazio

AU - Boiardi, Luigi

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Objective. To investigate whether infliximab has a steroid-sparing effect in the treatment of patients with polymyalgia rheumatica (PMR) who are resistant to corticosteroid (CS) therapy and have had CS-related side effects. Methods. In a pilot study, infliximab 3 mg/kg was administered at weeks 0, 2, and 6 in 4 patients with relapsing PMR who were not able to reduce their prednisone dose below 7.5-12.5 mg/day and who had experienced multiple vertebral fractures. The patients were regularly monitored for clinical signs/symptoms and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 (IL-6) during the one-year followup period. Results. Two patients had a complete response to infliximab with clinical remission 2 weeks after the first infusion. At this time ESR and IL-6 values were normal and the patients were able to suspend prednisone. Normal ESR, CRP, and IL-6 levels persisted after the suspension of infliximab and prednisone during the followup period, paralleling the clinical remission. The third patient had a complete and persistent clinical remission 2 weeks after the first infusion, although IL-6 levels remained elevated during the followup period despite the normalization of ESR values. These 3 patients were symptom-free with normal ESR and CRP at the end of 1-year of followup. The fourth patient had continuous clinical activity associated with persistently elevated acute phase reactants, although IL-6 levels measured during followup were lower compared to baseline values and the patient was able to reduce prednisone dosage to 5 mg/day. Conclusion. Our encouraging results suggest that a controlled study may assess the efficacy of infliximab as CS-sparing drug in PMR.

AB - Objective. To investigate whether infliximab has a steroid-sparing effect in the treatment of patients with polymyalgia rheumatica (PMR) who are resistant to corticosteroid (CS) therapy and have had CS-related side effects. Methods. In a pilot study, infliximab 3 mg/kg was administered at weeks 0, 2, and 6 in 4 patients with relapsing PMR who were not able to reduce their prednisone dose below 7.5-12.5 mg/day and who had experienced multiple vertebral fractures. The patients were regularly monitored for clinical signs/symptoms and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 (IL-6) during the one-year followup period. Results. Two patients had a complete response to infliximab with clinical remission 2 weeks after the first infusion. At this time ESR and IL-6 values were normal and the patients were able to suspend prednisone. Normal ESR, CRP, and IL-6 levels persisted after the suspension of infliximab and prednisone during the followup period, paralleling the clinical remission. The third patient had a complete and persistent clinical remission 2 weeks after the first infusion, although IL-6 levels remained elevated during the followup period despite the normalization of ESR values. These 3 patients were symptom-free with normal ESR and CRP at the end of 1-year of followup. The fourth patient had continuous clinical activity associated with persistently elevated acute phase reactants, although IL-6 levels measured during followup were lower compared to baseline values and the patient was able to reduce prednisone dosage to 5 mg/day. Conclusion. Our encouraging results suggest that a controlled study may assess the efficacy of infliximab as CS-sparing drug in PMR.

KW - Infliximab

KW - Polymyalgia rheumatica

KW - Relapsing disease

UR - http://www.scopus.com/inward/record.url?scp=12444282780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444282780&partnerID=8YFLogxK

M3 - Article

C2 - 12672196

AN - SCOPUS:12444282780

VL - 30

SP - 760

EP - 763

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -